Showing results (61-70 of 79) with videos related to
Sort By:
Pageof 8
Future Oncology (London, England)|August 9, 2025
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomitingRudolph M Navari, Timothy Tyler, Naoki Inui, et al.Critical Reviews in Oncology/Hematology|August 17, 2019
Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysisRonald Chow, Matti Aapro, Rudolph M Navari, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 9, 2005
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group studyRudolph M Navari, Lawrence H Einhorn, Steven D Passik, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 22, 2007
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group studyRudolph M Navari, Lawrence H Einhorn, Patrick J Loehrer, et al.The Journal of Extra-Corporeal Technology|December 15, 2011
Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastographyMark Walsh, Scott G Thomas, Janet C Howard, et al.The New England Journal of Medicine|July 14, 2016
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and VomitingRudolph M Navari, Rui Qin, Kathryn J Ruddy, et al.Cancer Letters|May 26, 2004
The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) miceMark A Suckow, Linda S Gutierrez, Christina A Risatti, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 16, 2016
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysisLeonard Chiu, Ronald Chow, Marko Popovic, et al.The Lancet. Oncology|August 15, 2015
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trialLee S Schwartzberg, Manuel R Modiano, Bernardo L Rapoport, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 6, 2020
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic ChemotherapyEric J Roeland, Kathryn J Ruddy, Thomas W LeBlanc, et al.Pageof 8